Central/peripheral fat mass ratio is associated with increased risk of hypertension in hiv-infected patients

Journal of Clinical Hypertension

Volumn 14, Issue 9, 2012, Pages 593-600

  Freitas, Paula ^a   Carvalho, Davide ^a   Santos, Ana Cristina ^a,b   Madureira, António José ^a   Xerinda, Sandra ^a   Martinez, Esteban ^c   Pereira, Jorge ^d   Sarmento, António ^a   Medina, José Luís ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS RATIO; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-RETROVIRAL AGENTS; ARTERIAL PRESSURE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERTENSION; MALE; RISK;

EID: 84865717240     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00671.x     Document Type: Article

References (47)

1. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-F70.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
3. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019-1026.
4. Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension. AIDS. 2001;15:805-807.
5. Galli M, Ridolfo AL, Gervasoni C. Cardiovascular disease risk factors in HIV-infected patients in the HAART era. Ann N Y Acad Sci. 2001;946:200-213.
6. Fantoni M, Del Borgo C, Autore C, Barbaro G. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Ital Heart J. 2002;3:294-299.
7. Duong M, Buisson M, Cottin Y, et al. Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review. Clin Cardiol. 2001;24:690-694.
8. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab. 2001;12:413-419.
9. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
10. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
11. Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001;15:2001-2010.
12. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci. 1999;317:232-237.
13. Gazzaruso C, Sacchi P, Garzaniti A, et al. Prevalence of metabolic syndrome among HIV patients. Diabetes Care. 2002;25:1253-1254.
14. Lundgren JD, Behrens G, Collins S, et al. Guidelines, prevention and management of non-infectious co-morbidities in HIV. EACS guidelines-Version 5-2, 2009.
15. Palacios R, Santos J, Garcia A, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med. 2006;7:10-15.
16. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377-1382.
17. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953-960.
18. Thiebaut R, El-Sadr WM, Friis-Moller N, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10:811-823.
19. Bergersen BM, Sandvik L, Dunlop O, et al. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22:731-736.
20. Jerico C, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens. 2005;18:1396-1401.
21. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
22. Garg A. Lipodystrophies. Am J Med. 2000;108:143-152.
23. Bjornstad PG, Semb BK, Trygstad O, Seip M. Echocardiographic assessment of cardiac function and morphology in patients with generalised lipodystrophy. Eur J Pediatr. 1985;144:355-359.
24. Bjornstad PG, Foerster A, Ihlen H. Cardiac findings in generalized lipodystrophy. Acta Paediatr Suppl. 1996;413:39-43.
25. Hegele RA, Anderson CM, Wang J, et al. Association between nuclear lamin A/C R482Q muation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension and diabetes. Genome Res. 2000;10:652-658.
26. Human immunodeficiency virus (HIV) infection codes and new codes for Kaposi's sarcoma. MMWR Recomm Rep. 1991;40(RR-9):1-18.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
28. WHO. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committe. Geneva: WHO; 1995.
29. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
30. Freitas P, Santos AC, Carvalho D, et al. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197-203.
31. Freitas P, Carvalho D, Souto S, et al. Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis. 2011;11:246.
32. Freitas P, Carvalho D, Santos AC, et al. Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. J Endocrinol Invest. 2011;34(10): e321-e329.
33. Freitas P, Carvalho D, Santos AC, et al. Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy. J Endocrinol Invest. 2011;2011 Dec 16. [Epub ahead of print].
34. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
35. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
36. Bonnet E, Delpierre C, Sommet A, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom. 2005;8:287-292.
37. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord. 1993;17:187-196.
38. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology. 1999;211:283-286.
39. De Macedo ME, Lima MJ, Silva AO, et al. Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study. Rev Port Cardiol. 2007;26:21-39.
40. Crane HM, Grunfeld C, Harrington RD, Kitahata MM. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 2009;10:496-503.
41. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831-843.
42. Karlsson C, Lindell K, Ottosson M, et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83:3925-3929.
43. Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J. 1986;111:932-940.
44. Mikkelsen KL, Wiinberg N, Hoegholm A, et al. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am J Hypertens. 1997;1(Pt 1):483-491.
45. Lee DH, Ha MH, Kim JR, et al. Effects of smoking cessation on changes in blood pressure and incidence of hypertension: a 4-year follow-up study. Hypertension. 2001;37:194-198.
46. Okubo Y, Suwazono Y, Kobayashi E, Nogawa K. An association between smoking habits and blood pressure in normotensive Japanese men: a 5-year follow-up study. Drug Alcohol Depend. 2004;73:167-174.
47. Omvik P. How smoking affects blood pressure. Blood Press. 1996;5:71-77.